Astragalin (kaempferol-3-O-β-D-glucoside) exerted an anti-inflammatory effect through NF-κB pathway inhibition and attenuated murine colitis and can be used as a potential therapeutic agent for IBD (49). Here, NFKB1 is linked to inflammatory bowel disease.